Search

Displaying results 2241 - 2250 of 8468 in total
  1. Drug

    Lanthanum carbonate

    go.drugbank.com/drugs/DB06792
    Approved

    Lanthanum carbonate is a phosphate binder marketed under the trade name Fosrenol by Shire Pharmaceuticals. It is a large pill that requires thorough chewing to avoid choking and other gastrointestinal adverse effects. It is used to treat...

  2. Drug

    Netupitant

    go.drugbank.com/drugs/DB09048
    ApprovedInvestigational

    Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic che...

  3. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol … Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class.

    Products: ATAZANAVIR (AS SULFATE) CAPSULES 300 MG., ATAZANAVIR ( AS SULFATE ) CAPSULES 150 MG
  4. Drug

    Dotatate gallium Ga-68

    go.drugbank.com/drugs/DB13925
    ApprovedInvestigationalWithdrawn

    Dotatate gallium (Ga-68) is a somatostatin-2 receptor analog which is radiolabeled with gallium 68 as a positron-emitting radioisotope. … [A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016.

  5. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals. … [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]

  6. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627] … It has been studied for the treatment of estrogen-dependent conditions such as uterine fibroids and endometriosis.

  7. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [A193014] Molnupiravir was granted approval by the UK's Medicines and Health products Regulatory Agency (MHRA) on 4 November 2021 to prevent severe outcomes such as hospitalization and death due to … [A193014] A [remdesivir] resistant mutant mouse hepatitis virus has also been shown to have increased sensitivity to N4-hydroxycytidine.

  8. Drug

    Mirvetuximab soravtansine

    go.drugbank.com/drugs/DB12489
    ApprovedInvestigational

    This decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024. … [L50306] In October 2024, it was approved in the EU for the same indication. [L52640]

  9. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

  10. Drug

    Apixaban

    go.drugbank.com/drugs/DB06605
    ApprovedInvestigational

    Apixaban was approved by the FDA on December 28, 2012[L6043]. … Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic